Beyond Cancer Reports Early Clinical Activity and Favorable Safety Profile with Interim Data from Phase 1 UNO Trial [Yahoo! Finance]
Beyond Air, Inc. (XAIR)
Company Research
Source: Yahoo! Finance
Beyond Air™ Data was published in the Online Itinerary Planner for the 2026 AACR Annual Meeting, and is scheduled to be presented at the meeting on April 19th GARDEN CITY, N.Y., March 17, 2026 (GLOBE NEWSWIRE) -- Beyond Cancer, Ltd., a clinical stage biotechnology company developing ultra-high concentration nitric oxide (UNO) as an investigational immunotherapeutic for solid tumors and subsidiary of Beyond Air, Inc. (NASDAQ: XAIR), today announced early signs of clinical activity and a favorable safety and tolerability profile from its Phase 1 clinical trial evaluating a single intratumoral UNO injection administered as monotherapy. These data were included in an Online Itinerary Planner issued today for the American Association for Cancer Research (AACR) Annual Meeting 2026, which is scheduled to be held from April 17-22, 2026 at the San Diego Convention Center in San Diego, California. The Phase 1 trial (NCT05351502) was a clinical proof-of-concept trial that assessed the int
Show less
Read more
Impact Snapshot
Event Time:
XAIR
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
XAIR alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
XAIR alerts
High impacting Beyond Air, Inc. news events
Weekly update
A roundup of the hottest topics
XAIR
News
- Beyond Air (XAIR) had its "buy" rating reaffirmed by D. Boral Capital. They now have a $10.00 price target on the stock.MarketBeat
- Beyond Cancer Reports Early Clinical Activity and Favorable Safety Profile with Interim Data from Phase 1 UNO TrialGlobeNewswire
- Beyond Air to Participate in the 38th Annual Roth Conference in March [Yahoo! Finance]Yahoo! Finance
- Beyond Air to Participate in the 38th Annual Roth Conference in MarchGlobeNewswire
- Beyond Air (XAIR) had its "buy" rating reaffirmed by D. Boral Capital. They now have a $10.00 price target on the stock.MarketBeat
XAIR
Earnings
- 8/12/25 - Miss
XAIR
Sec Filings
- 2/17/26 - Form SCHEDULE
- 2/17/26 - Form SCHEDULE
- 2/13/26 - Form 8-K
- XAIR's page on the SEC website